Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.46-1.13%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TPST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
TPST — CFO transition
Dated 2026-10-30
CFO — Constance Ames: The CFO resigned for personal reasons, but the company immediately appointed a qualified external successor, mitigating the negative impact of the departure.
Why it matters: The reported 100% complete response rate came from 15 evaluable patients. More follow-up can test how well those responses last.
Watch forAn update reports lasting complete responses and no Grade 3 or higher CRS or ICANS in REDEEM-1.
Also watch forAn update reports response loss, serious CRS or ICANS, or a lower response rate in a larger patient group.
Why it matters: Early patient data can test whether this delivery approach works in people. The release set an initial data window.
Watch forTempest or Senlang reports early clinical data by June 30, 2027. The report includes patient results and safety findings.
Also watch forNo early clinical data is reported by June 30, 2027. Or, the results show serious safety concerns or weak activity.
Why it matters: Starting the study would move TPST-2003 beyond trial preparation. The company named manufacturing work as a key step.
Supportive ifTempest reports that it has opened the first patient slot or enrolled the first patient in its planned U.S. registrational study.
Worry ifA company update says the study has not started, or that manufacturing or trial start has been delayed.
Why it matters: Tempest reported $0.8 million in cash at June 30 and later disclosed new stock financing. Updated cash and spending show how much room it has to fund trials.
Watch forThe November 4 report gives cash above $0.8 million and enough detail to show the new funds support planned trial work.
Also watch forThe report gives cash below $0.8 million, warns of a funding shortfall, or shows new funds are not enough to support planned trials.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $1,010 loss on $10,000 · 10.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,534 loss on $10,000 · 95.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.